Bio-Techne Corporation
Bio-Techne Corporation (TECH) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · TECH · as of Jun 8, 2026
Key Statistics
Explore Bio-Techne Corporation Data
tech stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 25 · Buy rate: 72.0%
The TECH analyst consensus is Buy, based on ratings from 25 Wall Street analysts over the past 3 months. The average 12-month price target is $60.33, representing +16.04% upside from the current price of $51.99.
Competitors & Peers
tech competitorsTECH
BMRN
CAI
CORT
EXEL
JAZZStock Performance
Full HistoryAbout Bio-Techne Corporation
Bio-Techne Corporation together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. T…
what is bio-techne corporation · tech stock overview · bio-techne corporation company profile · who is bio-techne corporation ceo · tech NASDAQ · bio-techne corporation headquarters · bio-techne corporation business segments
About Stock Overview & Key Data
Bio-Techne Corporation (TECH) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Feb 9, 1989. As of the latest trading session, TECH stock price is $51.99, with a market capitalization of $8.1B. The stock has returned +4.23% over the past 12 months and -11.60% year-to-date.
According to 25 Wall Street analysts, the consensus rating for Bio-Techne Corporation stock is Buy, with an average 12-month price target of $60.33. In fiscal year 2025, Bio-Techne Corporation reported revenue of $1.2B and net income of $73.4M. For detailed data — including Bio-Techne Corporation revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Bio-Techne Corporation (TECH) stock price is $51.99. The stock is traded on NASDAQ under the ticker symbol TECH. The 52-week range is $43.20 – $72.16.